万拉法新与丁螺环酮治疗广泛性焦虑症对照研究  

A clinical control study of venlafaxine and buspirone in the treatment of general anxiety disorder.

作　　者：刘玉厚[1] 徐敏秀[1] 郑振宝[1] 

机构地区：[1]山东省临沂市精神卫生中心,276005

出　　处：《山东精神医学》2003年第1期19-21,共3页Shangdong Archives of Psychiatry

摘　　要：目的 验证万拉法新治疗广泛性焦虑症的疗效及副反应。方法 对符合CCMD-2-R广泛性焦虑症诊断标准的患者,随机分为万拉法新组和丁螺环酮组治疗6周。于治疗前及治疗后1、2、4、6周末用汉密尔顿焦虑量表(HAMA)、焦虑自评量表(SAS)、临床总体评定量表(CGI)及副反应量表(TESS)评定临床疗效及副反应。结果 万拉法新与丁螺环酮疗效相当,起效时间相近,没有严重副反应。结论 万拉法新治疗广泛性焦虑症疗效确切,副反应少而轻,患者服药依从性好。Objective To verify the clinical efficacy and the side effects of venlafaxine in the treatment of general anxiety disorder. Methods 68 patients meeting CCMD-2-R criteria for general anxiety disorder were randomly assigned to venlafaxine group(n = 35) and buspirone group(n = 33)for 6 weeks. Effects and side effects were evaluated with Hamilton Anxiety Seale(HAMA),Self-Rating Anxiety Scale(SAS) Clinical Global Impression Scale(CGI)and Treatment Emergent Symptoms Scale(TESS)before and after 1,2,4, 6-weeks treatment respectively. Results The therapeutic efficacy in venlafaxine group was similar to that in buspirone. Compared with buspirone , venlafaxine had few side effects. Conclusion It is suggested that venlafaxine was effective in the treatment of general anxiety disorder and produced fewer side effects.

关 键 词：广泛性焦虑症 万拉法新 丁螺环酮 

分 类 号：R749.72[医药卫生—神经病学与精神病学]